Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 26,340 Shares of Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 26,340 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $2.43, for a total transaction of $64,006.20. Following the transaction, the insider owned 3,522,188 shares of the company’s stock, valued at $8,558,916.84. This represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Price Performance

NASDAQ:DYAI opened at $0.94 on Monday. Dyadic International Inc. has a one year low of $0.65 and a one year high of $1.35. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The firm has a market cap of $34.27 million, a price-to-earnings ratio of -4.09 and a beta of 1.15. The firm’s fifty day moving average is $0.77 and its two-hundred day moving average is $0.83.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Research analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DYAI. Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. Marathon Capital Management increased its stake in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares in the last quarter. Apis Capital Advisors LLC purchased a new position in shares of Dyadic International in the 3rd quarter valued at about $1,817,000. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the 3rd quarter worth about $190,000. Finally, Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Institutional investors and hedge funds own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.